Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes

Jia-Yuan Zhang; Fiona Hamey; Dominik Trzupek; Marius Mickunas; Mercede Lee; Leila Godfrey; Jennie H. M. Yang; Marcin L. Pekalski; Jane Kennet; Frank Waldron-Lynch; Mark L. Evans; Timothy I. M. Tree; Linda S. Wicker; John A. Todd; Ricardo C. Ferreira

doi:10.1038/s41467-022-34162-3

Nature Communications (Nov 2022)

Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes

Jia-Yuan Zhang,
Fiona Hamey,
Dominik Trzupek,
Marius Mickunas,
Mercede Lee,
Leila Godfrey,
Jennie H. M. Yang,
Marcin L. Pekalski,
Jane Kennet,
Frank Waldron-Lynch,
Mark L. Evans,
Timothy I. M. Tree,
Linda S. Wicker,
John A. Todd,
Ricardo C. Ferreira

Affiliations

Jia-Yuan Zhang: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford
Fiona Hamey: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford
Dominik Trzupek: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford
Marius Mickunas: Department of Immunobiology, King’s College London, School of Immunology and Microbial Sciences
Mercede Lee: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford
Leila Godfrey: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford
Jennie H. M. Yang: Department of Immunobiology, King’s College London, School of Immunology and Microbial Sciences
Marcin L. Pekalski: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford
Jane Kennet: Wellcome-MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge
Frank Waldron-Lynch: Vertex Pharmaceuticals, Vertex Cell & Gene Therapies
Mark L. Evans: Wellcome-MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge
Timothy I. M. Tree: Department of Immunobiology, King’s College London, School of Immunology and Microbial Sciences
Linda S. Wicker: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford
John A. Todd: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford
Ricardo C. Ferreira: JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford

DOI: https://doi.org/10.1038/s41467-022-34162-3
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 17

Abstract

Read online

Low-dose interleukin-2 is showing promise in the treatment of several autoimmune inflammatory diseases. Here authors map the trajectory of cellular and transcriptional changes in type 1 diabetes patients receiving an interval dosing interleukin-2 regimen, which shows an anti-inflammatory gene expression signature shared by all immune cell types analysed, persisting for at least a month after ending treatment.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal